SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Global surveillance and control of hepatitis C. J Viral Hepat 1999; 6: 3547.
    Direct Link:
  • 2
    Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 13351374.
  • 3
    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. N Engl J Med 2009; 361: 580593.
  • 4
    Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli F. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008; 372: 19621976.
  • 5
    Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005; 294: 218228.
  • 6
    Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2: e124.
  • 7
    Lacchetti C, Guyatt G. Therapy and validity: surprising results of randomized controlled trials. In: GuyattG and RennieD, eds. Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA Press; 2002: 247265.
  • 8
    Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JPA, Thabane L. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? International J Epidemiol 2009; 38: 276286.
  • 9
    Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 2004; 57: 11241130.
  • 10
    Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Colloboration, 2008. Available at: www.cochrane-handbook.org. Accessed 28 May 2009.
  • 11
    Awad T, Thorlund K, Hauser G, Mabrouk M, Stimac D, Gluud C. Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C. Cochrane Database of Systematic Reviews 2009; 1: CD005642.
  • 12
    Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609613.
  • 13
    Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982989.
  • 14
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408412.
  • 15
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 15391558.
  • 16
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924926.
  • 17
    Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008; 61: 763769.
  • 18
    Brok J, Thorlund K, Gluud C, Wetterslev J. Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta-analyses. Int J Epidemiol 2009; 38: 287298.
  • 19
    Witthoeft T, Hueppe D, John C, Goelz J, Meyer U, Heyne R, et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the practice study: Abstracts of the 43rd Annual Meeting of the European Association for the Study of the Liver [Abstract]. HEPATOLOGY 2008; 48: 315.
  • 20
    Berak H, Horban A, Wasilewski M, Stanczak JJ, Kolakowska-Rzadzka A. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes-12 week virological response analysis. HEPATOLOGY 2005; 42( Suppl.): S1.
  • 21
    Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004; 9: 491497.
  • 22
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Viral Hepat 2007; 14: 721729.
  • 23
    Kolakowska A, Berok H, Wasilewski M, Horbon A. Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study. HEPATOLOGY 2008; 48: 1278.
  • 24
    Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. HEPATOLOGY 2009; 49: 2231.
  • 25
    Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology 2010 Jan; 138(1): 108115.
  • 26
    Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, et al. Peg-interferon alpha-2a versus peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008; 28: 623630.
  • 27
    Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). HEPATOLOGY 2006; 45: 204213.
  • 28
    Sinha S, Gulur P, Patel V, Hage-Nassar G, Tenner S. A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. Am J Gastroenterol 2004; 99: 237.
  • 29
    Yenice N, Mehtap O, Gumrah M, Arican N. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006; 17: 9498.
  • 30
    Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology 2010 Jan; 138: 116122.
  • 31
    Adeel AB, Xiaoqiang W, Charity GM. Effect of hepatitis C virus and its treatment on survival. HEPATOLOGY 2009; 50: 387392.
  • 32
    Hirofumi U, Sherri OS, Katsuhiro H, Kotaro K, Fumisato S, Shuji K, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. HEPATOLOGY 2009; 50: 393399.
  • 33
    Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol 2007; 46: 734742.
  • 34
    Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921928.
  • 35
    Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews 2009; 1: MR000006.
  • 36
    Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008; 5: e191.
  • 37
    Dickersin K, Rennie D. Registering clinical trials. JAMA 2003; 290: 516523.
  • 38
    Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 11671170.
  • 39
    Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252260.
  • 40
    Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of Gabapentin for off-label use. N Engl J Med 2009; 361: 19631971.
  • 41
    Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C, et al. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement. BMJ 2005; 330: 956958.
  • 42
    World Health Organization. International Clinical Trials Registry Platform (ICTRP) 2009. Available at: www.who.int/ictrp/en/. Accessed 13 May 2009.
  • 43
    Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001; 285: 19921995.